<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03990974</url>
  </required_header>
  <id_info>
    <org_study_id>20190236</org_study_id>
    <nct_id>NCT03990974</nct_id>
  </id_info>
  <brief_title>Postoperative Antimicrobial Prophylaxis Versus Placebo for Infection Prevention in HCC After Liver Resection</brief_title>
  <acronym>HCC</acronym>
  <official_title>Postoperative Antimicrobial Prophylaxis Versus Placebo for Infection Prevention in Hepatocellular Carcinoma After Liver Resection: A Multi-center, Randomized, Open-labelled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a multi-center, double-blinded, randomized (1:1) clinical trial. The aim is to
      compare the postoperative infection rate between the 3 days postoperative AMP group and the
      placebo group in HCC patients undergoing hepatectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial includes two phase. The first phase is the internal pilot study to explore the
      expulsion rate and recruited population. The second phase is the main phase III trial.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    There were difficulties in implementation
  </why_stopped>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>30-day postoperative infection rate</measure>
    <time_frame>30 days after hepatectomy</time_frame>
    <description>the incidence rate of postoperative infection occurred in 30 days after surgery, including surgical site infections, distant infection or infection from unknown sources</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surgical site infection rate</measure>
    <time_frame>30 days after hepatectomy</time_frame>
    <description>the incidence rate of surgical site infection, including infections of the incision or organ or space that occur after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complication rate</measure>
    <time_frame>3 months after hepatectomy</time_frame>
    <description>the incidence rate of postoperative complications, grading as Clavien-Dindo grades</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe infection rate</measure>
    <time_frame>30 days after hepatectomy</time_frame>
    <description>the incidence rate of postoperative complications over grade 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant infection rate</measure>
    <time_frame>30 days after hepatectomy</time_frame>
    <description>the incidence rate of distant infections, including respiratory system infection, urinary system infection, catheter related infections or sepsis (defined as fever (temperature ≥38 ℃) or elevated white blood cell (&gt; 10 x10^9 / L) accompanied by sputum, urine, catheter secretions, or blood culture positive.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">458</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Postoperative Infection</condition>
  <arm_group>
    <arm_group_label>Postoperative antimicrobial prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive postoperative antimicrobial prophylaxis for 3 days in 24 hours after hepatectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No postoperative antimicrobial prophylaxis</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients will receive no antibiotics after hepatectomy, unless the clinicians suggest he/she need antibiotics to treat or prevent infection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>postoperative antimicrobial prophylaxis</intervention_name>
    <description>The drugs are all common antibiotics used to prevent postoperative infection in each hospital.</description>
    <arm_group_label>Postoperative antimicrobial prophylaxis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No postoperative antimicrobial prophylaxis</intervention_name>
    <description>Patients will receive no antibiotics after hepatectomy unless necessary.</description>
    <arm_group_label>No postoperative antimicrobial prophylaxis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: over 18 years;

          -  Diagnosed as primary HCC according to the EASL criteria and plan to receive
             hepatectomy;

          -  Child-Pugh A class;

          -  No history of antibiotics in 1 week before surgery, except for antimicrobial
             prophylaxis in the 24h before surgery.

          -  No evidence of infection during preoperational assessment

        Exclusion Criteria:

          -  Underwent hepatectomy combined with resection of other organs, except for gallbladder;

          -  Found obvious infection during operation;

          -  Combination with other operations, such as biliary reconstruction or tube drainage,
             bile duct exploration and stone remove, etc.;

          -  Allergic to the antibiotics used in the 24h before surgery;

          -  Emergency surgery;

          -  Tumor rupture;

          -  Did not underwent hepatectomy because of any reasons;

          -  Admission to ICU after surgery;

          -  ASA grade ≥ 3;

          -  Denial of informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 18, 2019</study_first_submitted>
  <study_first_submitted_qc>June 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2019</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Ming Kuang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Anti-Infective Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

